GL1X · GenesisL1 explorer

Research workbench

Cryo-EM structure of the VRC310 clinical trial, vaccine-elicited, human antibody 310-030-1D06 Fab in complex with an H1 NC99 ha trimer

Analyse Cryo-EM structure of the VRC310 clinical trial, vaccine-elicited, human… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7MFG
Type
protein
Length
2,121 residues
Chains
12
Method
electron microscopy
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Hemagglutinin HA1 chain; Hemagglutinin HA2 chain; 310-030-1D06 heavy; 310-030-1D06 light
UniProt
Q6WG00, Q289M7
Ligands
NAG, BMA
Pockets
20 · best druggability 0.72

Structure

electron microscopy · 4 distinct chains · 18% helix, 30% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, C, GHemagglutinin HA1 chainprotein32211% helix, 34% strandQ6WG00
B, D, IHemagglutinin HA2 chainprotein15755% helix, 10% strandQ289M7
H, E, J310-030-1D06 heavyprotein1205% helix, 37% strand—
L, F, K310-030-1D06 lightprotein1080% helix, 37% strand—

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 27 copies · chains B, D, I, A, C, G
  • BMA · beta-D-mannopyranose · sugar · 3 copies · chains L, F, K

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

20 pockets found on a 1 Å grid, 9 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15430.720.8056empty
23900.710.8252empty
35170.700.8057empty
43030.660.8247empty
52960.660.8247empty

Interfaces

27 interfaces between chains.

  • C–D · 2590 Ų buried · 37 hydrogen bonds · protein-protein
  • A–B · 2581 Ų buried · 38 hydrogen bonds · protein-protein
  • G–I · 2580 Ų buried · 34 hydrogen bonds · protein-protein
  • D–I · 945 Ų buried · 9 hydrogen bonds · protein-protein
  • B–D · 942 Ų buried · 9 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 27 disulfide, 24 glycan (disulfide, N-glycosylation).

Compared structures

  • 7MFG · Cryo-EM structure of the VRC310 clinical trial, vaccine-elicited, human antibody… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.